company background image
XENE

Xenon Pharmaceuticals NasdaqGM:XENE Stock Report

Last Price

US$37.76

Market Cap

US$2.7b

7D

10.7%

1Y

-2.8%

Updated

04 Dec, 2023

Data

Company Financials +

Xenon Pharmaceuticals Inc.

NasdaqGM:XENE Stock Report

Mkt Cap: US$2.7b

XENE Stock Overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

XENE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Xenon Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xenon Pharmaceuticals
Historical stock prices
Current Share PriceUS$37.76
52 Week HighUS$43.75
52 Week LowUS$27.99
Beta1.31
1 Month Change14.84%
3 Month Change-3.94%
1 Year Change-2.76%
3 Year Change243.59%
5 Year Change439.43%
Change since IPO259.62%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Oct 21
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Jun 22
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Feb 15
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Oct 27
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Xenon started at outperform at Raymond James on experimental epilepsy drug

Oct 19

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Sep 22
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Putting Xenon Pharmaceuticals Back In The Spotlight

Sep 06

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Aug 29

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Jun 13
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Sizing Up Xenon Pharmaceuticals

Dec 13

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Nov 12
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Aug 05
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

May 13
Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Apr 14
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?

Mar 16
Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?

Shareholder Returns

XENEUS BiotechsUS Market
7D10.7%3.8%0.9%
1Y-2.8%-5.8%13.6%

Return vs Industry: XENE exceeded the US Biotechs industry which returned -7.8% over the past year.

Return vs Market: XENE underperformed the US Market which returned 11.7% over the past year.

Price Volatility

Is XENE's price volatile compared to industry and market?
XENE volatility
XENE Average Weekly Movement7.7%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: XENE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: XENE's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996208Ian Mortimerhttps://www.xenon-pharma.com

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.

Xenon Pharmaceuticals Inc. Fundamentals Summary

How do Xenon Pharmaceuticals's earnings and revenue compare to its market cap?
XENE fundamental statistics
Market CapUS$2.72b
Earnings (TTM)-US$175.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-15.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XENE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$161.27m
Gross Profit-US$161.27m
Other ExpensesUS$14.20m
Earnings-US$175.46m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did XENE perform over the long term?

See historical performance and comparison